Cargando…

The Efficacy Profile of Rotigotine During the Waking Hours in Patients With Advanced Parkinson's Disease: A Post Hoc Analysis

Transdermal delivery of rotigotine maintains stable plasma concentrations for 24 hours. Three phase 3 studies of rotigotine as add-on to levodopa in advanced Parkinson's disease showed a significant reduction in “off” time from baseline to end of maintenance (EoM). However, detailed analyses ov...

Descripción completa

Detalles Bibliográficos
Autores principales:	LeWitt, Peter A., Poewe, Werner, Elmer, Lawrence W., Asgharnejad, Mahnaz, Boroojerdi, Babak, Grieger, Frank, Bauer, Lars
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2016
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4791317/ https://www.ncbi.nlm.nih.gov/pubmed/26882318 http://dx.doi.org/10.1097/WNF.0000000000000133

Ejemplares similares

Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson’s Disease: A Post Hoc Analysis
por: Giladi, Nir, et al.
Publicado: (2016)

Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson’s disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER
por: LeWitt, Peter A., et al.
Publicado: (2012)

Impulse control disorder related behaviours during long‐term rotigotine treatment: a post hoc analysis
por: Antonini, A., et al.
Publicado: (2016)

Efficacy of Rotigotine at Different Stages of Parkinson’s Disease Symptom Severity and Disability: A Post Hoc Analysis According to Baseline Hoehn and Yahr Stage
por: Giladi, Nir, et al.
Publicado: (2016)

Rotigotine transdermal system and evaluation of pain in patients with Parkinson’s disease: a post hoc analysis of the RECOVER study
por: Kassubek, Jan, et al.
Publicado: (2014)

Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson’s disease
por: Hauser, Robert A, et al.
Publicado: (2016)

Transdermal rotigotine for the perioperative management of Parkinson’s disease
por: Wüllner, Ullrich, et al.
Publicado: (2010)

Overnight switch from ropinirole to transdermal rotigotine patch in patients with Parkinson disease
por: Kim, Han-Joon, et al.
Publicado: (2011)

Rotigotine Effects on Early Morning Motor Function and Sleep in Parkinson's Disease: A Double-Blind, Randomized, pLacebo-Controlled Study (RECOVER)
por: Trenkwalder, Claudia, et al.
Publicado: (2011)

Rotigotine's effect on PLM-associated blood pressure elevations in restless legs syndrome: An RCT
por: Bauer, Axel, et al.
Publicado: (2016)

Impact of Impulse Control Disorders on Sleep-Wake Regulation in Parkinson's Disease
por: Djamshidian, Atbin, et al.
Publicado: (2015)

Behavioral and Neurophysiological Effects of Transdermal Rotigotine in Atypical Parkinsonism
por: Moretti, Davide Vito, et al.
Publicado: (2014)

Efficacy and safety of rotigotine in elderly patients with Parkinson’s disease in comparison with the non-elderly: a post hoc analysis of randomized, double-blind, placebo-controlled trials
por: Nomoto, Masahiro, et al.
Publicado: (2017)

Transdermal rotigotine for the perioperative management of restless legs syndrome
por: Högl, Birgit, et al.
Publicado: (2012)

Effect of Concomitant Medications on the Safety and Efficacy of Extended-Release Carbidopa-Levodopa (IPX066) in Patients With Advanced Parkinson Disease: A Post Hoc Analysis
por: LeWitt, Peter A., et al.
Publicado: (2018)

Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson’s disease: an open-label study
por: Kim, Jong-Min, et al.
Publicado: (2015)

Effects of Night-Time Use of Rotigotine on Nocturnal Symptoms in Parkinson's Disease
por: Vallderiola, Francesc, et al.
Publicado: (2015)

Transdermal rotigotine patch in Parkinson’s disease with a history of intestinal operation
por: Ogawa, Takashi, et al.
Publicado: (2018)

Rotigotine transdermal patch and sleep in Parkinson’s disease: where are we now?
por: Rosa-Grilo, Miguel, et al.
Publicado: (2017)

Treatment of moderate to severe restless legs syndrome: 2-year safety and efficacy of rotigotine transdermal patch
por: Högl, Birgit, et al.
Publicado: (2010)

Effects of Nabilone on Sleep Outcomes in Patients with Parkinson's Disease: A Post‐hoc Analysis of NMS‐Nab Study
por: Peball, Marina, et al.
Publicado: (2022)

Rotigotine Transdermal Patch in Parkinson’s Disease: A Systematic Review and Meta-Analysis
por: Zhou, Chang-Qing, et al.
Publicado: (2013)

A Systematic Review of the Usage of Rotigotine During Early and Advanced Stage Parkinson's
por: Rajendran, Avanthika, et al.
Publicado: (2023)

Norepinephrine: the next therapeutics frontier for Parkinson's disease
por: LeWitt, Peter A
Publicado: (2012)

Rotigotine is safe and efficacious in Atypical Parkinsonism Syndromes induced by both α-synucleinopathy and tauopathy
por: Moretti, Davide Vito, et al.
Publicado: (2014)

Preparation and evaluation of rotigotine-loaded implant for the treatment of Parkinson’s disease and its evolution study
por: Wang, Aiping, et al.
Publicado: (2016)

Rotigotine Objectively Improves Sleep in Parkinson's Disease: An Open-Label Pilot Study with Actigraphic Recording
por: Calandra-Buonaura, Giovanna, et al.
Publicado: (2016)

Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson’s disease treatment
por: Bi, Chenchen, et al.
Publicado: (2016)

Vascular parkinsonism sensitive to rotigotine therapy is found in aged patients: a clinical case description
por: Zarola, Flora
Publicado: (2018)

Rotigotine transdermal system: a short review
por: Bunten, Sabine, et al.
Publicado: (2006)

Levodopa/rotigotine: Lack of efficacy: case report
Publicado: (2022)

Delirious episode secondary to rotigotine: the psychotic patch
por: Andreo Vidal, M. A., et al.
Publicado: (2023)

Comparing the Incidence of Falls/Fractures in Parkinson’s Disease Patients in the US Population
por: Kalilani, Linda, et al.
Publicado: (2016)

Post-hoc Analysis of Outcome of Intravenous Thrombolysis in Infarcts of Infratentorial Localization in the WAKE-UP Trial
por: Galinovic, Ivana, et al.
Publicado: (2019)

Transdermal Rotigotine Improves Sleep Fragmentation in Parkinson's Disease: Results of the Multicenter, Prospective SLEEP-FRAM Study
por: Pagonabarraga, Javier, et al.
Publicado: (2015)

Critical appraisal of rotigotine transdermal system in management of Parkinson’s disease and restless legs syndrome – patient considerations
por: Kesayan, Tigran, et al.
Publicado: (2015)

Restless legs syndrome: differential diagnosis and management with rotigotine
por: Merlino, Giovanni, et al.
Publicado: (2009)

EHMTI-0081. Use of rotigotine in chronic cluster headache
por: Savi, L, et al.
Publicado: (2014)

The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II
por: Rocha, José-Francisco, et al.
Publicado: (2021)

The safety/tolerability of opicapone when used early in Parkinson's disease patients with levodopa-induced motor fluctuations: A post-hoc analysis of BIPARK-I and II
por: Rocha, José-Francisco, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6d40c9c0p3qggctos7lgrck3q8